Hospira Collaborates With Celltrion

Hospira has entered into a business co-operation agreement with South Korea-based Celltrion and Celltrion Healthcare.

Under the distribution agreement, the companies would collaborate on manufacturing and supply of the products. After regulatory approval, Hospira and Celltrion would co-exclusively market the drugs, with the products independently commercialised under each party’s brand name.

Christopher Begley, chairman and CEO at Hospira, said: “This partnership gives Hospira access to Celltrion’s biogenerics portfolio. We’re excited to work with Celltrion, and we look forward to expanding Hospira’s presence in these significant biogenerics markets.”

Jung-Sin Seo, CEO and chairman at Celltrion, said: “We believe this partnership will benefit both companies by combining Hospira’s broad outreach with Celltrion’s advanced biologic manufacturing capabilities.”

Reportedly, the financial details of the agreement were not disclosed. The agreement signed is expected to lead to a final agreement in the coming months.